Effects of AMPA receptor positive modulators on amphetamine- and dizocilpine-induced locomotion

European Journal of Pharmacology

Volumn 332, Issue 2, 1997, Pages 115-119

  Vanover, Kimberly E ^a  

^a Department of Pharmacokinetics and Drug Metabolism   (United States)

Author keywords

AMPA ( amino 3 hydroxy 5 methylisoxazole 4 propionic acid); Antipsychotic; Behavior; Dopamine; Mouse; Schizophrenia

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; AMINO ACID RECEPTOR AFFECTING AGENT; AMPA RECEPTOR; AMPHETAMINE; DIZOCILPINE; HALOPERIDOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; HYPERACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; DIOXOLES; DIZOCILPINE MALEATE; DOPAMINE ANTAGONISTS; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HALOPERIDOL; LOCOMOTION; MALE; MICE; PIPERIDINES; RECEPTORS, AMPA;

EID: 0030857778     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01103-5     Document Type: Article

References (26)

1. Arai, A., Kessler, M., Rogers, G., Lynch, G., 1996. Effects of a memory-enhancing drug on DL-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus. J. Pharmacol. Exp. Ther. 278, 627-638.
2. Arnt, J., 1995. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur. J. Pharmacol. 283, 55-62.
3. Bristow, L.J., Landon, L., Saywell, K.L., Tricklebank, M.D., 1995. The glycine/NMDA receptor antagonist, L-701,324 reverses isolation-induced deficits in prepulse inhibition in the rat. Psychopharmacology 118, 230-232.
4. Bristow, L.J., Flatman, K.L., Hutson, P.H., Kulagowski, J.J., Leeson, P.D., Young, L., Tricklebank, M.D., 1996. The atypical neuroleptic profile of the glycine/N-methyl-D-aspartate receptor antagonist, L-701-324, in rodents. J. Pharmacol. Exp. Ther. 277, 578-585.
5. Bubser, M., Tzschentke, T., Hauber, W., 1995. Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats. J. Neural Transm. Gen. Sect. 101, 115-126.
6. Burns, L.H., Everitt, B.J., Kelley, A.E., Robbins, T.W., 1994. Glutamate-dopamine interactions in the ventral striatum: Role in locomotor activity and responding with conditional reinforcement. Psychopharmacology 115, 516-528.
7. Carboni, E., Imperato, A., Perezzani, L., Di Chiara, G., 1989. Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 28, 653-661.
8. Corbett, R., Camacho, F., Woods, A.T., Kerman, L.L., Fishkin, R.J., Brooks, K., Dunn, R.W., 1995. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology 120, 67-74.
9. Freed, W.J., Bing, L.A., Wyatt, R.J., 1984. Effects of neuroleptics on phencyclidine (PCP)-induced locomotor stimulation in mice. Neuropharmacology 23, 175-181.
10. Goff, D.C., Tsai, G., Manoach, D.S., Coyle, J.T., 1995. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiatry 152, 1213-1215.
11. Hauber, W., Andersen, R., 1993. The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine. Naunyn-Schmiedebergs Arch. Pharmacol. 348, 486-490.
12. Hoffman, D.C., 1992. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J. Neural. Transm. 89, 1-10.
13. Iversen, S.D., 1995. Interactions between excitatory amino acids and dopamine systems in the forebrain: Implications for schizophrenia and Parkinson's disease. Behav. Pharmacol. 6, 478-491.
14. Javitt, D.C., Zukin, S.R., 1991. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148, 1301-1308.
15. Javitt, D.C., Zylberman, I., Zukin, S.R., Heresco-Levy, U., Lindenmayer, J.-P., 1994. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry 151, 1234-1236.
16. Johnson, S.A., Larson, J., Luu, N.T., Lutz, D.L., Rogers, G., Lynch, G., 1996. Antagonism of methamphetamine-induced hyperactivity in rats by specific facilitation of AMPA-receptor-mediated glutamatergic transmission (657.12). Soc. Neurosci. Abstr. 22, 1676.
17. Kuczenski, R., Segal, D., 1989. Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J. Neurosci. 9, 2051-2065.
18. Larson, J., Lieu, T., Petchpradub, V., LeDuc, B., Ngo, H., Rogers, G.A., Lynch, G., 1995. Faciliatation of olfactory learning by a modulator of AMPA receptors. J. Neurosci. 15, 8023-8030.
19. Larson, J., Quach, C.N., LeDuc, B.Q., Nguyen, A., Rogers, G.A., Lynch, G., 1996. Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats. Brain Res. 738, 353-356.
20. Olney, J.W., Farber, N.B., 1995. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52, 998-1007.
21. Rao, T.S., Kim, H.S., Lehmann, J., Martin, L.L., Wood, P.L., 1989. Differential effects of phencyclidine (PCP) and ketamine on mesocortical and mesostriatal dopamine release in vivo. Life Sci. 45, 1065-1072.
22. Snyder, S.H., 1976. The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor. Am. J. Psychiatry 133, 197-202.
23. Staubli, U., Rogers, G., Lynch, G., 1994. Facilitation of glutamate receptors enhances memory. Proc. Natl. Acad. Sci. USA 91, 777-781.
24. Willins, D.L., Wallace, L.J., Miller, D.D., Uretsky, N.J., 1992. α-Amino-3-hydroxy-5-methylisoxazole-4-proprionate/kainate receptor antagonists in the nucleus accumbens and ventral pallidum decrease the hypermotility response to psychomotor stimulant drugs. J. Pharmacol. Exp. Ther. 260, 1145-1151.
25. Willins, D.L., Narayanan, S., Wallace, L.J., Uretsky, N.J., 1993. The role of dopamine and AMPA/kainate receptors in the nucleus accumbens in the hypermotility response to MK801. Pharmacol. Biochem. Behav. 45, 881-887.
26. Zetterström, T., Sharp, T., Marsden, C.A., Ungerstedt, U., 1983. In vivo measurement of dopamine and its metabolites by intracerebral dialysis: Changes after D-amphetamine. J. Neurochem. 41, 1769-1773.